fluocinolone acetonide

S01BA15

Forms & Strengths

Adult Dosing

Diabetic macular edema (intravitreal implant): 1 implant (0.18 mg) to the affected eye once, non-bioerodible lasting up to 36 months
Chronic noninfectious uveitis affecting the posterior segment (intravitreal implant): 1 implant (0.19 mg) to the affected eye once, lasting up to 36 months
Inflammatory dermatoses (topical): Apply thin layer to affected area 2 to 4 times daily depending on formulation
Otitis externa (otic oil): 5 drops into the affected ear(s) once daily for 7 days

Pediatric Dosing

Inflammatory dermatoses (topical, pediatric >2 years): Apply sparingly to affected area 2 to 3 times daily
Safety and efficacy of intravitreal implants in pediatric patients have not been established

Indications

Diabetic macular edema
Chronic noninfectious uveitis affecting the posterior segment of the eye
Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses
Otitis externa due to susceptible organisms (when combined with or formulated as otic oil)

Mechanism of Action

Potent synthetic fluorinated corticosteroid
Binds to glucocorticoid receptors, suppressing inflammatory cytokine production, reducing capillary permeability, and inhibiting leukocyte migration

Contraindications

Active viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis, vaccinia, and varicella
Mycobacterial and fungal infections of the eye
Known hypersensitivity to fluocinolone acetonide or any component of the formulation

Adverse Reactions

Drug Interactions

Concomitant use of CYP3A4 inhibitors (e.g., ritonavir, itraconazole) may potentially increase systemic exposure of topical or systemic absorption
Co-administration with other agents that increase intraocular pressure may potentiate IOP elevation

Curated Content: Needs Vetting Before Put to Clinical Use